In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses results from an interim analysis of the DESTINY-Breast09 trial, which were presented at ASCO Annual Meeting.The ...

Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus trastuzumab and pertuzumab across patients with HER2-positive metastatic breast ...